Evidence map›Paper›PMID 42775453›Full record

ReviewClinical pharmacology and therapeutics2026

The Hidden Cost of QTc Assessment: A Quantitative Weight of Evidence Framework to Eliminate Structural False Positives and Restore the Lost Opportunity Cost of Abandoned Medicines.

Matthew M Abernathy, Charles T Benson, Derek J Leishman

Abstract readReview
In one paragraph

Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Matthew M AbernathyEli Lilly and Company, Indianapolis, Indiana, USA.
Charles T BensonEli Lilly and Company, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-7681-5746
Derek J LeishmanEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The regulatory framework for QTc assessment has been optimized against false negatives while ignoring the false positives that silently remove efficacious medicines from development. False positives arise from three independent, compounding sources. First, a structural source: sensitive tests applied in low-prior populations generate predominantly false positives as a mathematical inevitability. Second, a measurement artifact: patch-clamp electrophysiology systematically biases hERG IC

Identifiers

PMID42775453
PMCPMC13598688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.